Kim Jung Sue, Aviles Diego H, Silverstein Douglas M, Leblanc Pamela L, Matti Vehaskari V
Department of Pediatrics, Louisiana State University Health Sciences Center and Children's Hospital, New Orleans, LA, USA.
Pediatr Transplant. 2005 Apr;9(2):162-9. doi: 10.1111/j.1399-3046.2005.00263.x.
Tacrolimus has become an effective alternative to cyclosporine as a component of primary immunosuppression in pediatric renal transplant patients, but the information on the pharmacokinetic characteristics of tacrolimus in young patients is still limited. The primary objective of this study was to determine the effect of patient age, ethnicity, and concurrent steroid administration on tacrolimus pharmacokinetics in pediatric renal transplant patients. The study population consisted of 30 pediatric patients, age 1.5-18.6 yr, who received a kidney transplant between July 1999 and February 2004. After twice daily dosing was stabilized based on clinical judgment, at least 5 days postoperatively, tacrolimus levels were drawn prior to, and 1, 2, 4, 8, and 12 h after the morning dose. The mean dose of tacrolimus was 0.12 mg/kg/dose. Mean trough level was 11.9 +/- 5.0 ng/mL. Mean area under the curve (AUC) was 192 +/- 84 with a range of 78-360 h x (ng/mL). The correlation between trough level and AUC was only fair (r = 0.74); later time points correlated better with AUC, and an excellent correlation (r = 0.96) was obtained between the mean of trough and 2-h level (C(2)) and AUC. There was a negative correlation between age and dose per body weight (r = -0.68). African-American patients had marginally lower drug exposure with similar dosing. Three age groups (<5, 5-12, and >12 yr) were compared with respect to dosing and AUC. Despite similar AUC in all three groups, the mean dose per kg required to achieve the AUC was 2.7- and 1.9-fold higher in the <5 and 5-12-yr groups, respectively, compared with the >12-yr group. Nine of the 30 patients were on a totally steroid-free regimen. Their tacrolimus dose and trough levels were similar to those of steroid-exposed patients, but their mean AUC was 41% higher. Our results show an inverse correlation between age and required tacrolimus dose, wide interindividual variation, and greater exposure with steroid-free regimen despite no change in trough level.
他克莫司已成为儿科肾移植患者初始免疫抑制方案中环孢素的有效替代药物,但关于他克莫司在年轻患者体内药代动力学特征的信息仍然有限。本研究的主要目的是确定患者年龄、种族以及同时使用类固醇对儿科肾移植患者他克莫司药代动力学的影响。研究对象包括30名年龄在1.5至18.6岁之间的儿科患者,他们于1999年7月至2004年2月期间接受了肾移植手术。根据临床判断,术后至少5天,在每日两次给药稳定后,于晨服他克莫司之前以及服药后1、2、4、8和12小时采集血样检测他克莫司水平。他克莫司的平均剂量为0.12mg/kg/次。平均谷浓度为11.9±5.0ng/mL。平均曲线下面积(AUC)为192±84,范围为78 - 360h×(ng/mL)。谷浓度与AUC之间的相关性一般(r = 0.74);较晚时间点与AUC的相关性更好,谷浓度与2小时血药浓度(C(2))的平均值与AUC之间具有良好的相关性(r = 0.96)。年龄与每体重剂量之间存在负相关(r = -0.68)。非裔美国患者在剂量相似的情况下药物暴露略低。比较了三个年龄组(<五岁、5至12岁和>12岁)的给药情况和AUC。尽管三组的AUC相似,但与>12岁组相比,<5岁和5至12岁组达到AUC所需的每千克平均剂量分别高出2.7倍和1.9倍。30名患者中有9名采用完全无类固醇方案。他们的他克莫司剂量和谷浓度与使用类固醇的患者相似,但平均AUC高出41%。我们的结果显示年龄与所需他克莫司剂量呈负相关,个体间差异较大,并且在谷浓度不变的情况下,无类固醇方案的药物暴露更高。